The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2021

  • Pages
    539

  • View Count
    16142

Example Insights

Biologics-Fill-Finish-Service-Providers-Market-Context Biologics-Fill-Finish-Service-Providers-Market-Distribution-by-Number-of-Instances Biologics-Fill-Finish-Service-Providers-Market-Distribution-by-Type-of-Biologic-Offered Biologics-Fill-Finish-Service-Providers-Market-Distribution-by-Scale-of-Operation-and-Region
Biologics-Fill-Finish-Service-Providers-Market-Geographical-Distribution-by-Location-of-BFF-Facility Biologics-Fill-Finish-Service-Providers-Market-Competitiveness-Analysis Biologics-Fill-Finish-Service-Providers-Market-Recent-Expansions-and-Partnership-Activity Biologics-Fill-Finish-Service-Providers-Market-Capacity-Analysis
Biologics-Fill-Finish-Service-Providers-Market-Current-and-Future-Demand-across-Different-Geographies Biologics-Fill-Finish-Service-Providers-Market-Demand-vs-Supply-Analysis Biologics-Fill-Finish-Service-Providers-Market-Distribution-by-Type-of-Packaging Biologics-Fill-Finish-Service-Providers-Market-Future-Forecast

 

Overview

In order to meet the anticipated future demand for biologics fill / finish services in the American and European markets, contract service providers based in these regions have made significant investments in accruing additional capacity for drug product manufacturing and fill / finish

-- Chief Commercial Officer, large-sized company

Over the last few decades, as a consequence of the therapeutic efficacy and favorable safety profiles of various marketed candidates and those under development, the biopharmaceutical industry has witnessed tremendous growth. The overwhelming success of this upcoming class of products has prompted both established and novice pharmaceutical innovators to develop assets in this arena. Currently, there are close to 400 approved products and more than 4,000 biologic candidates in clinical trials, being developed for the treatment of a wide variety of diseases. As the number of commercialized products and clinical stage therapy candidates increases, the demand for adequate manufacturing capacities and affiliated capabilities is also on the rise. In the production cycle, the (aseptic) fill / finish process is a crucial step. Biopharmaceutical fill / finish operations are relatively more complicated, involving sterilization of all affiliated components before use, filling in a sterile environment, and the use of appropriate post filling sterilization methods. Even minute errors during the aforementioned step can have catastrophic consequences, resulting in heavy losses for the innovator company. Therefore, it is important for companies to establish fill / finish related expertise and build / maintain the necessary infrastructure. 

To meet some the abovementioned challenges, drug developers have not hesitated to outsource fill / finish operations to capable contract service providers. Currently, around 170 companies claim to be actively providing fill / finish services for biologics. As is generally the trend among service providers, stakeholders in this domain are making active attempts to adopt the latest technological innovations, in order to meet the growing demand for fill / finish services, reduce cost of operation / increase efficiency, and comply to evolving safety and regulatory requirements, and thereby, differentiate themselves amidst the competition. Over the last few years, the fill / finish services industry has witnessed more than 120 instances of expansion, most of which were intended to increase capacity. We believe that the companies involved this segment of the industry are likely to continue to undertake similar initiatives to cater to the growing needs of their clientele. In addition, significant partnership activity between sponsors and services providers has also been reported in the recent past; a substantial number of deals were observed to have been inked between vaccine developers and CMOs, focused on the fulfilment of fill / finish requirements for multiple vaccines against COVID-19. Considering the anticipated growth in the biologics market, the corresponding opportunity for fill / finish service providers is expected to grow at a steady pace over the coming years.

Scope of the Report

The “Biologics Fill / Finish Services Market (2nd Edition) by Type of Primary Packaging Container (Ampoules, Cartridges, Syringes and Vials), Type of Biologic (Antibodies, Cell Therapy, Gene Therapy, Oligonucleotides, Recombinant Proteins, Vaccines and  Others), Scale of Operation (Preclinical / Clinical and Commercial), Key Therapeutic Areas, Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the biologics fill / finish service providers. The study features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies offering fill / finish services for biopharmaceuticals / biologics, along with analyses based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials),  type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.
  • A detailed competitiveness analysis of the fill / finish service providers based in different geographies offering services across various packaging types, based on supplier strength (in terms of experience and company size), service strength (in terms of number of fill / finish facilities, geographical reach and scale of operation) and types of biologics handled.     
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific. Each profile provides an overview of the company, information on its service offerings, fill / finish facilities, financial information (if available), details on partnerships, expansions and recent awards and accolades, and an informed future outlook. 
  • An analysis of the partnerships and collaborations focused on the fill / finish operations of biologic drug products, which were established since 2013, based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of biologics involved and location of fill / finish facilities involved. 
  • A review of the recent expansions (since 2015) undertaken by biologics fill / finish service providers, including a detailed analysis based on various parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of packaging form, types of services offered, types of biologics involved, scale of operation (preclinical, clinical and commercial), the most active players and geographical location of the added facility.
  • An estimate of the global fill / finish capacity for filling of biologics, by taking into consideration the capacities of various fill / finish service providers. The fill / finish capacity has been analyzed in terms of number of units and volume of biologics filled, across various type of packaging containers (ampoules, cartridges, syringes, and vials), for the service providers distributed on the basis of company size (small, mid-sized and large) and geographical location (North America, Europe and Asia Pacific).
  • An informed estimate of the annual demand for fill / finish of the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of these products. 
  • A regional capability assessment framework, which compares the fill / finish capabiility across key geographies, based on a number of parameters, such as the number of biologic fill / finish service providers, number of biologic fill / finish facilities, number of biologic fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologic fill / finish capacity in that particular geographical region.
  • An analysis to identify the key performance indicators for service providers engaged in this domain, based on information gathered via secondary research and primary research.
  • A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes, providing a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
  • A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations, providing a list of suppliers providing the ready-to-use components.
  • A discussion on the potential growth areas, such as growing biopharmaceutical pipeline, increasing outsourcing of fill / finish operations, rising focus on self-administration enabling drug delivery devices and growing opportunities in the Asia-Pacific region.

One of the key objectives of this report was to estimate the current market size and the future opportunity in the biologics fill / finish services market, over the coming decade. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of  [A] types of packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and  others), [D] key therapeutic areas (autoimmune disorders, cardiovascular disorders, infectious disorders, oncological disorders and other disorders), and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Japan, China, South Korea, India and Australia), MENA, Latin America and Rest of the World). To account for the uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
    
The opinions and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:
Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)

  • Matt Delaney (Vice President Business Development & Marketing, ‎Cytovance Biologics)
  • Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
  • Ales Sima (Business Development Manager, Oncomed Manufacturing) 
  • Amit Chandra (Technology Watch Manager, Yposkesi)
  • Jos Vergeest (International Business Developer, HALIX)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading contract service providers with expertise in fill / finish services for biologics?
  • In which regions are majority of the biologic fill / finish facilities located?
  • What percentage of ampoules, cartridges, vials and syringes are filled annually with biologics?
  • Which partnership models are most commonly adopted by stakeholders in this industry?
  • What type of expansion initiatives are being carried out by players in this domain?
  • What is the current, global demand for biologic fill / finish services?
  • How is the current and future market opportunity likely to be distributed across key market segments

Contents

Chapter Outline

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biologics fill / finish service providers market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to biopharmaceuticals and contract manufacturing. The chapter features a detailed discussion on the need for outsourcing within the biopharmaceutical industry and highlights the key operations outsourced by the biologic drug developers, including fill / finish. Additionally, the chapter highlights the key considerations for selecting a fill / finish service provider, along with the benefits and risks associated with outsourcing fill / finish operations.

Chapter 4 provides an overview of the overall biologics fill / finish contract services landscape. It includes information on close to 170 contract service providers currently engaged in this domain. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill / finish facilities, types of packaging form (ampoules, cartridges, syringes and vials),  type of biologic filled (ADC, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial), type of additional services offered (lyophilization, labelling, quality testing, storage and distribution services) and including details on fill / finish capacity and fill volume range.

Chapter 5 features a detailed competitiveness analysis of the service providers based in North America, Europe and Asia-Pacific. The companies within each geography have been compared on the basis of the type of packaging used for fill / finish services, supplier strength (considering experience and company size of service provider), service strength (considering number of fill / finish facilities, geographical reach, number of additional services offered and highest scale of operation) and type of biologics involved.

Chapter 6 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in North America. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook. 

Chapter 7 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Europe. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook. 

Chapter 8 includes detailed profiles of the key players in the biopharmaceutical fill / finish contract services market in Asia-Pacific. Each profile features a brief overview of the company, its overall contract service offerings highlighting the capabilities of fill / finish facilities (if available), financial information (if available), recent developments and an informed future outlook. 

Chapter 9 features a detailed analysis of the various collaborations and partnerships that have been inked amongst players since 2013. It includes a brief description of the partnership models (including acquisition, supply agreement, service alliance, merger and joint venture) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, the scale of operation of the project, focus area, types of services provided, types of biologics and location of the facilities where the project is to be executed. 

Chapter 10 presents a detailed analysis of the expansions undertaken by various service providers to enhance fill / finish capabilities,  based on various parameters, including year of expansion, type of expansion, geographical location of the facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services offered, types of biologics filled, and expansion details (in terms of new area added to the existing facilities). It also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features a comprehensive analysis of the global fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The global biopharmaceutical fill / finish capacity has been distributed across number of packaging units, type of packaging container (ampoules, cartridges, syringes and vials), company size of the manufacturer (small, mid-sized and large) and geographical location (North America, Europe and Asia-Pacific).

Chapter 12 provides an estimate of the annual demand for fill / finish of top 25 biologics (in number of units of packaging containers), based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products. 

Chapter 13 features an analysis on the key performance indicators of service providers based on information available for top-ten biopharmaceutical players on various public platforms, as well as inputs obtained from primary research.

Chapter 14 presents a regional capability assessment framework, which compares the fill / finish capability across key geographies, based on a number of parameters, such as the number of biologics fill / finish service providers, number of biologics fill / finish facilities, number of biologics fill / finish partnerships inked in that particular geographical region, number of facility expansions and installed biologics fill / finish capacity in that particular geographical region.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics’ fill / finish services market till the year 2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] scale of operation (preclinical, clinical and commercial), [C] types of biologics filled (antibodies, cell therapy, gene therapy, oligonucleotides, recombinant proteins, vaccines and  others), [D] key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications, and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia (Japan, China, South Korea and India), MENA and Latin America and Rest of the World).

Chapter 16 includes a discussion on the various potential growth drivers for the biologics fill / finish services market, which takes into account the opportunities associated with the growing biopharmaceutical pipeline, increase in outsourcing of fill / finish operations, rising focus on self-administration of drugs / therapies and opportunities in the Asia-Pacific region.

Chapter 17 is a case study focused on use of robotic systems in fill / finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill / finish operations, highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies providing robots for use in manufacturing processes carried in the pharmaceutical sector.  

Chapter 18 is a case study on the use of ready-to-use packaging components in the aseptic fill / finish operations. It also provides a list of suppliers providing ready-to-use components.

Chapter 19 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the biologics fill / finish services market.

Chapter 20 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing and fill / finish domain. In this study, we spoke to Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Matt Delaney (Vice President Business Development & Marketing, ‎Cytovance Biologics), Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International), Ales Sima (Business Development Manager, oncomed manufacturing), Amit Chandra (Technology Watch Manager, Yposkesi) and Jos Vergeest (International Business Developer, HALIX).

Chapter 21 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Biologics
3.3. Need for Outsourcing Biologics-related Operations
3.4. Introduction to Contract Manufacturing
3.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.5.1. Biologics Fill / Finish Operations
3.6. Basic Guidelines for Selecting a Fill / Finish Service Provider
3.7. Advantages of Outsourcing Fill / Finish Operations
3.8. Risks and Challenges of Outsourcing Fill / Finish Operations

4. BIOLOGICS FILL / FINISH SERVICE PROVIDERS: COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Fill / Finish Facilities
4.2.5. Analysis by Type of Packaging
4.2.6. Analysis by Type of Biologics Filled
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Additional Services Offered
4.2.9. Information on Fill / Finish Capacity

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology and Key Parameters

5.3. Biologics Fill / Finish Service Providers in North America
5.4.1. Players Offering Services in Ampoules
5.4.2. Players Offering Services in Cartridges
5.4.3. Players Offering Services in Syringes
5.4.4. Players Offering Services in Vials

5.5. Biologics Fill / Finish Service Providers in Europe
5.5.1. Players Offering Services in Ampoules
5.5.2. Players Offering Services in Cartridges
5.5.3. Players Offering Services in Syringes
5.5.4. Players Offering Services in Vials

5.6. Biologics Fill / Finish Service Providers in Asia-Pacific and RoW
5.6.1. Players Offering Services in Ampoules
5.6.2. Players Offering Services in Cartridges
5.6.3. Players Offering Services in Syringes
5.6.4. Players Offering Services in Vials

6. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. AbbVie Contract Manufacturing
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Financial Information
6.2.4. Recent Developments and Future Outlook

6.3. BioPharma Solutions
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. BioReliance
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments and Future Outlook

6.5. Catalent Biologics
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments and Future Outlook

6.6. Patheon
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Financial Information
6.6.4. Recent Developments and Future Outlook

7. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE
7.1. Chapter Overview
7.2. Boehringer Ingelheim BioXcellence
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Financial Information
7.2.4. Recent Developments and Future Outlook

7.3. Lonza
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Financial Information
7.3.4. Recent Developments and Future Outlook

7.4. Pierre Fabre
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Financial Information
7.4.4. Recent Developments and Future Outlook

7.5. Recipharm
7.5.1. Company Overview
7.5.2. Service Portfolio
7.5.3. Financial Information
7.5.4. Recent Developments and Future Outlook

7.6. Wacker Biotech
7.6.1. Company Overview
7.6.2. Service Portfolio
7.6.3. Financial Information
7.6.4. Recent Developments and Future Outlook

8. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Asymchem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Financial Information
8.2.4. Recent Developments and Future Outlook

8.3. Samsung Biologics
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Financial Information
8.3.4. Recent Developments and Future Outlook

8.4. Syngene
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Financial Information
8.4.4. Recent Developments and Future Outlook

8.5. Takara Bio
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Financial Information
8.5.4. Recent Developments and Future Outlook

8.6. WuXi Biologics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Financial Information
8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Service
9.3.5. Analysis by Type of Process
9.3.6. Analysis by Type of Biologic Involved
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Geographical Analysis
9.3.8.1. Intercontinental and Intracontinental Agreements
9.3.8.2. Analysis by Geographical Location of Facilities

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Biologics Fill / Finish Service Providers: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Packaging Form
10.2.4. Analysis by Type of Service Offered
10.2.5. Analysis by Type of Biologic Involved
10.2.6. Analysis by Type of Biologic Involved and Scale of Operation
10.2.7. Most Active Players: Analysis by Type of Service
10.2.8. Geographical Analysis
10.2.9. Expansions in North America: Analysis by Type of Service Offered and Type of
 Biologic Involved
10.2.10. Expansions in Europe: Analysis by Type of Service and Type of Biologic
10.2.11. Expansions in Asia-Pacific: Analysis by Type of Service and Type of Biologic

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Fill / Finish Capacity (by Number of Units Filled)
11.3.1. Analysis by Type of Packaging
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Fill / Finish Facilities

11.4. Global Fill / Finish Capacity (by Fill Volume)
11.4.1. Analysis by Type of Packaging
11.4.2. Analysis by Company Size
11.4.3. Analysis by Scale of Operation
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Location of Fill / Finish Facilities

11.5. Global Fill / Finish Capacity for Ampoules (by Number of Units Filled)
11.5.1 Analysis by Company Size
11.5.2 Analysis by Scale of Operation
11.5.3. Analysis by Location of Headquarters
11.5.4 Analysis by Location of Fill / Finish Facilities

11.6. Global Fill / Finish Capacity for Ampoules (by Fill Volume)
11.6.1. Analysis by Company Size
11.6.2. Analysis by Scale of Operation
11.6.3. Analysis by Location of Headquarters
11.6.4. Analysis by Location of Fill / Finish Facilities

11.7. Global Fill / Finish Capacity for Cartridges (by Number of Units Filled)
11.7.1. Analysis by Company Size
11.7.2. Analysis by Scale of Operation
11.7.3. Analysis by Location of Headquarters
11.7.4. Analysis by Location of Fill / Finish Facilities

11.8. Global Fill / Finish Capacity for Cartridges (by Fill Volume)
11.8.1. Analysis by Company Size
11.8.2. Analysis by Scale of Operation
11.8.3. Analysis by Location of Headquarters
11.8.4. Analysis by Location of Fill / Finish Facilities

11.9. Global Fill / Finish Capacity for Syringes (by Number of Units Filled)
11.9.1 Analysis by Company Size
11.9.2 Analysis by Scale of Operation
11.9.3. Analysis by Location of Headquarters
11.9.4 Analysis by Location of Fill / Finish Facilities

11.10. Global Fill / Finish Capacity for Syringes (by Fill Volume)
11.10.1. Analysis by Company Size
11.10.2. Analysis by Scale of Operation
11.10.3. Analysis by Location of Headquarters
11.10.4. Analysis by Location of Fill / Finish Facilities

11.11. Global Fill / Finish Capacity for Vials (by Number of Units Filled)
11.11.1 Analysis by Company Size
11.11.2 Analysis by Scale of Operation
11.11.3. Analysis by Location of Headquarters
11.11.4. Analysis by Location of Fill / Finish Facilities

11.12. Global Fill / Finish Capacity for Vials (by Fill Volume)
11.12.1. Analysis by Company Size
11.12.2. Analysis by Scale of Operation
11.12.3. Analysis by Location of Headquarters
11.12.4. Analysis by Location of Fill / Finish Facilities

11.13. Conclusion

12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Global Demand for Biologics Fill / Finish Services
12.3.1. Analysis by Type of Packaging
12.3.2. Analysis by Type of Biologic
12.3.3. Analysis by Therapeutic Area
12.3.4. Analysis by Geographical Location

12.4. Demand and Supply Analysis

13. KEY PERFORMANCE INDICATORS FOR BIOLOGIC MANUFACTURING AND FILL / FINISH
13.1. Chapter Overview
13.2. Biologics Manufacturing and Fill / Finish: Key Performance Indicators
13.2.1. Financial Indicators
13.2.1.1. Big Pharma Perspective
13.2.1.2. Contract Manufacturers’ Perspective

13.2.2. Process and Capability-related Indicators
13.2.2.1. Big Pharma Perspective
13.2.2.2. Contract Manufacturers’ Perspective

13.2.3. Market Reputation-related Indicators
13.2.3.1. Big Pharma Perspective
13.2.3.2. Contract Manufacturers’ Perspective

13.2.4. Other Important Performance Indicators
13.3.5. Conclusion

14. REGIONAL CAPABILITY ASSESSMENT
14.1. Chapter Overview
14.2. Assumptions and Key Parameters
14.3. Biologics Fill / Finish Capabilities in North America
14.4. Biologics Fill / Finish Capabilities in Europe
14.5. Biologics Fill / Finish Capabilities in Asia-Pacific Region
14.6. Concluding Remarks

15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology
15.3. Overall Biologics Fill / Finish Services Market, 2021-2030
15.3.1. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging
15.3.2. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation
15.3.3. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic
15.3.4. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area
15.3.5. Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region
15.3.5.1 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries
15.3.5.2. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging
15.3.5.3. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation
15.3.5.4. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic
15.3.5.5. Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area
15.3.5.6. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries
15.3.5.7. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging
15.3.5.8. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation
15.3.5.9. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic
15.3.5.10. Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area
15.3.5.11. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries
15.3.5.12. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging
15.3.5.13. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.3.5.14. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.3.5.15. Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

15.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030
15.4.1. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation
15.4.2. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic
15.4.3. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area
15.4.4. Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region
15.4.4.1. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation
15.4.4.2. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic
15.4.4.3. Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area
15.4.4.4. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation
15.4.4.5. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic
15.4.4.6. Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area
15.4.4.7. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.4.4.8. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.4.4.9. Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

15.5. Biologics Fill / Finish Services Market for Cartridges, 2021-2030
15.5.1. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation
15.5.2. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic
15.5.3. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area
15.5.4. Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region
15.5.4.1. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation
15.5.4.2. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic
15.5.4.3. Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area
15.5.4.4. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation
15.5.4.5. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic
15.5.4.6. Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area
15.5.4.7. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.5.4.8. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.5.4.9. Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

15.6. Biologics Fill / Finish Services Market for Syringes, 2021-2030
15.6.1. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation
15.6.2. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic
15.6.3. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area
15.6.4. Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region
15.6.4.1. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation
15.6.4.2. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic
15.6.4.3. Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area
15.6.4.4. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation
15.6.4.5. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic
15.6.4.6. Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area
15.6.4.7. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.6.4.8. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.6.4.9. Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

15.7. Biologics Fill / Finish Services Market for Vials, 2021-2030
15.7.1. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation
15.7.2. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic
15.7.3. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area
15.7.4. Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region
15.7.4.1. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation
15.7.4.2. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic
15.7.4.3. Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area
15.7.4.4. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation
15.7.4.5. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic
15.7.4.6. Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area
15.7.4.7. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
15.7.4.8. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic
15.7.4.9. Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area

16. FUTURE GROWTH OPPORTUNITIES
16.1. Chapter Overview
16.2. Growing Biopharmaceutical Pipeline
16.3. Increase in Outsourcing of Fill / Finish Activities
16.4. Rising Focus on Self-Administration of Drugs
16.5. Advances in Aseptic Fill / Finish Technologies
16.6. Growing Opportunities in the Asia-Pacific Region

17. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS
17.1. Chapter Overview
17.2. Contract Service Providers: List of Fill / Finish Equipment
17.3. Role of Robotic Systems in Fill / Finish Operations
17.3.1. Types of Robots Used in Pharmaceutical Operations
17.3.2. Key Considerations for Selecting a Robotic System
17.3.3. Advantages of Robotic Systems
17.3.4. Disadvantages of Robotic Systems
17.4. Companies Providing Robots for Use in the Pharmaceutical Industry
17.5. Companies Providing Isolator based Aseptic Filling Systems
17.6. Concluding Remarks

18. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH
18.1. Chapter Overview
18.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
18.2.1. Advantages of Ready-to-Use Packaging Components
18.2.2. Disadvantages of Ready-to-Use Packaging Components
18.3. Companies Providing Ready-to-Use Packaging Components
18.4. Concluding Remarks

19. CONCLUDING REMARKS

20. INTERVIEW TRANSCRIPTS
20.1 Chapter Overview
20.2 IDT Biologika
20.2.1. Company Snapshot
20.2.1. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer

20.3 Cytovance Biologics
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Matt Delaney, Vice President of Business Development and Marketing

20.4. Syngene
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development

20.5 oncomed manufacturing
20.5.1. Company Snapshot
20.5.2. Interview Transcript: Ales Sima, Business Development Manager

20.6 Yposkesi
20.6.1. Company Snapshot
20.6.2. Interview Transcript: Amit, Technology Watch Manager

20.7 HALIX
20.7.1. Company Snapshot
20.7.2. Interview Transcript: Jos Vergeest, International Business Developer

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Various Types of Biologics
Figure 3.2 Types of Third-Party Service Providers
Figure 3.3 Commonly Outsourced Operations
Figure 3.4 Steps Involved in Fill / Finish of Biologics
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges of Outsourcing Biologics Fill / Finish Operations
Figure 4.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 4.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 4.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
Figure 4.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
Figure 4.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 4.8 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Figure 5.1 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in North America
Figure 5.2 Company Competitiveness Analysis: Players Offering Services in Ampoules (North America)
Figure 5.3 Company Competitiveness Analysis: Players Offering Services in Cartridges (North America)
Figure 5.4 Company Competitiveness Analysis: Players Offering Services in Syringes (North America)
Figure 5.5 Company Competitiveness Analysis: Players Offering Services in Vials (North America)
Figure 5.6 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in Europe
Figure 5.7 Company Competitiveness Analysis: Players Offering Services in Ampoules (Europe)
Figure 5.8 Company Competitiveness Analysis: Players Offering Services in Cartridges (Europe)
Figure 5.9 Company Competitiveness Analysis: Players Offering Services in Syringes (Europe)
Figure 5.10 Company Competitiveness Analysis: Players Offering Services in Vials (Europe)
Figure 5.11 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers in (Asia-Pacific and Rest of the World)
Figure 5.12 Company Competitiveness Analysis: Players Offering Services in Ampoules (Asia-Pacific and Rest of the World)
Figure 5.13 Company Competitiveness Analysis: Players Offering Services in Cartridges (Asia-Pacific and Rest of World)
Figure 5.14 Company Competitiveness Analysis: Players Offering Services in Syringes (Asia-Pacific and Rest of the World)
Figure 5.15 Company Competitiveness Analysis: Players Offering Services in Vials (Asia-Pacific and Rest of the World)
Figure 6.1 AbbVie Contract Manufacturing: Overview of Service Portfolio
Figure 6.2 AbbVie: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.3 BioPharma Solutions: Overview of Service Portfolio
Figure 6.4 BioReliance: Overview of Service Portfolio
Figure 6.5 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
Figure 6.6 Merck KGaA: Annual Revenues by Business Segmnent, 9M 2020 (EUR Billion)
Figure 6.7 Catalent Biologics: Overview of Service Portfolio
Figure 6.8 Catalent Biologics: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.9 Patheon: Overview of Service Portfolio
Figure 6.10 Thermo Fisher Scientific: Annual Revenues, 2014-9M 2020 (USD Billion)
Figure 7.1 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Figure 7.2 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Figure 7.3 Lonza: Overview of Service Portfolio
Figure 7.4 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
Figure 7.5 Pierre Fabre: Overview of Service Portfolio
Figure 7.6 Pierre Fabre: Annual Revenues, 2015 - 2019 (EUR Billion)
Figure 7.7 Recipharm: Overview of Service Portfolio
Figure 7.8 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
Figure 7.9 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
Figure 7.10 Wacker Biotech: Overview of Service Portfolio
Figure 7.11 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
Figure 8.1 Asymchem: Overview of Service Portfolio
Figure 8.2 Asymchem: Annual Revenues, 2015-2019 (USD Million)
Figure 8.3 ChemPartner: Overview of Service Portfolio
Figure 8.4 Samsung Biologics: Overview of Service Portfolio
Figure 8.5 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
Figure 8.6 Syngene: Overview of Service Portfolio
Figure 8.7 Syngene: Annual Revenues, FY 2016 – Q3 FY 2021 (INR Million)
Figure 8.8 Takara Bio: Overview of Service Portfolio
Figure 8.9 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
Figure 8.10 WuXi Biologics: Overview of Service Portfolio
Figure 8.11 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Service
Figure 9.5 Partnerships and Collaborations: Distribution by Types of Process
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Involved and Type of Service Offered
Figure 9.7 Partnerships and Collaborations: Most Active Players
Figure 9.8 Partnerships and Collaborations: Geographical Analysis
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
Figure 10.1 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Packaging Form
Figure 10.4 Recent Expansions: Distribution by Type of Expansion and Type of Service
Figure 10.5 Recent Expansions: Distribution by Type of Biologic Involved
Figure 10.6 Recent Expansions: Distribution by Type of Biologic Involved and Scale of Operation
Figure 10.7 Recent Expansions: Distribution by Geographical Location
Figure 10.8 Recent Expansions: Most Active Players
Figure 10.9 Recent Expansions: Distribution by Location of Expansion Project
Figure 10.10 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Figure 10.11 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
Figure 10.12 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
Figure 11.1 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
Figure 11.2 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
Figure 11.3 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
Figure 11.4 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
Figure 11.5 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
Figure 11.6 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
Figure 11.7 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
Figure 11.8 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
Figure 11.9 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.10 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
Figure 11.11 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
Figure 11.12 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Figure 11.13 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Figure 11.14 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
Figure 11.15 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.16 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.17 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.18 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.19 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.20 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.21 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.22 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.23 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.24 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.25 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.26 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.27 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.28 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.29 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.30 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.31 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.32 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.33 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.34 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.35 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
Figure 11.36 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Range of Capacity by Company Size (Thousand Units)
Figure 11.37 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.38 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.39 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.40 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
Figure 11.41 Global Fill / Finish Capacity for Syringes (by Fill Volume): Range of Capacity by Company Size (Liters)
Figure 11.42 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
Figure 11.43 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
Figure 11.44 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.45 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Figure 11.46 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Range of Capacity by Company Size
Figure 11.47 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Figure 11.48 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Figure 11.49 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Figure 11.50 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Kilo Liters)
Figure 11.51 Global Fill / Finish Capacity for Vials (by Fill Volume): Range of Capacity by Company Size (Kilo Liters)
Figure 11.52 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Figure 11.53 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Figure 11.54 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 12.1 Global Demand for Biologics Fill / Finish Services (Million Liters)
Figure 12.2 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
Figure 12.3 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic Involved (Kilo Liters)
Figure 12.4 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
Figure 12.5 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
Figure 12.6 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
Figure 13.1 Biologics Manufacturing and Fill / Finish: Key Performance Indicators (KPIs)
Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.3 Financial Indicators: Big Pharma Perspective
Figure 13.4 Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.5 Process / Capability-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.6 Process / Capability-related Indicators: Big Pharma Perspective
Figure 13.7 Process / Capability-related Indicators: Contract Manufacturers’ Perspective
Figure 13.8 Market Reputation-related Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.9 Market Reputation-related Indicators: Big Pharma Perspective
Figure 13.10 Market Reputation-related Indicators: Contract Manufacturers’ Perspective
Figure 13.11 Other Performance Indicators: Contract Manufacturers’ Perspective
Figure 14.1 Regional Capability Assessment: Biologic Fill / Finish Capabilities in North America
Figure 14.2 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Europe
Figure 14.3 Regional Capability Assessment: Biologic Fill / Finish Capabilities in Asia-Pacific and Rest of the World
Figure 14.4 Regional Capability Assessment: Comparison of Capabilities across Different Regions
Figure 15.1 Overall Biologics Fill / Finish Services Market, 2021-2030 (USD Billion)
Figure 15.2 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.3 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.4 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.5 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.6 Biologics Fill / Finish Services Market, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.7 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Countries (USD Million)
Figure 15.8 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.9 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.10 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.11 Biologics Fill / Finish Services Market in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.12 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Countries (USD Million)
Figure 15.13 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.14 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.15 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.16 Biologics Fill / Finish Services Market in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.17 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Countries (USD Million)
Figure 15.18 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging (USD Million)
Figure 15.19 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.20 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.21 Biologics Fill / Finish Services Market in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.22 Biologics Fill / Finish Services Market for Ampoules, 2021-2030 (USD Million)
Figure 15.23 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.24 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.25 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.26 Biologics Fill / Finish Services Market for Ampoules, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.27 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.28 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.29 Biologics Fill / Finish Services Market for Ampoules in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.30 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.31 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.32 Biologics Fill / Finish Services Market for Ampoules in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.33 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.34 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.35 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.36 Biologics Fill / Finish Services Market for Cartridges, 2021-2030 (USD Million)
Figure 15.37 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.38 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.39 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.40 Biologics Fill / Finish Services Market for Cartridges, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.41 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.42 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.43 Biologics Fill / Finish Services Market for Cartridges in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.44 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.45 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.46 Biologics Fill / Finish Services Market for Cartridges in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.47 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.48 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.49 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.50 Biologics Fill / Finish Services Market for Syringes, 2021-2030 (USD Million)
Figure 15.51 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.52 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.53 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.54 Biologics Fill / Finish Services Market for Syringes, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.55 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.56 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.57 Biologics Fill / Finish Services Market for Syringes in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.58 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.59 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.60 Biologics Fill / Finish Services Market for Syringes in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.61 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.62 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.63 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.64 Biologics Fill / Finish Services Market for Vials, 2021-2030 (USD Million)
Figure 15.65 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.66 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.67 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.68 Biologics Fill / Finish Services Market for Vials, 2021-2030: Distribution by Geographical Region (USD Million)
Figure 15.69 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.70 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.71 Biologics Fill / Finish Services Market for Vials in North America, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.72 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.73 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.74 Biologics Fill / Finish Services Market for Vials in Europe, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.75 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 15.76 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Type of Biologic (USD Million)
Figure 15.77 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 16.1 Growth Opportunities for Biologics Fill / Finish Service Providers
Figure 16.2 New Molecular Entities Approved by the FDA, 2011-2020
Figure 17.1 Key Considerations for Selecting a Robotic System
Figure 17.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 18.1 Key Drivers of Ready-to-Use Platform
Figure 19.1 Concluding Remarks: Current Biologic Fill / Finish Service Providers Market Landscape Summary
Figure 19.2 Concluding Remarks: Recent Partnerships
Figure 19.3 Concluding Remarks: Recent Expansions
Figure 19.4 Concluding Remarks: Capacity Analysis
Figure 19.5 Concluding Remarks: Demand Analysis
Figure 19.6 Concluding Remarks: Market Sizing and Opportunity Analysis for Biologic Fill / Finish Services Market

List Of Tables

Table 3.1 Best-Selling Drugs of 2019
Table 4.1 Biologics Fill / Finish Service Providers: List of Companies
Table 4.2 Biologics Fill / Finish Service Providers: Information on Type of Packaging
Table 4.3 Biologics Fill / Finish Service Providers: Information on Type of Biologic Involved
Table 4.4 Biologics Fill / Finish Service Providers: Information on Scale of Operation
Table 4.5 Biologics Fill / Finish Service Providers: Information on Additional Services Offered
Table 4.6 Biologics Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 6.1 Biologics Fill / Finish Service Providers in North America: List of Profiled Companies
Table 6.2 AbbVie Contract Manufacturing: Company Overview
Table 6.3 AbbVie Contract Manufacturing: Overview of Service Portfolio
Table 6.4 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 6.5 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 6.6 BioPharma Solutions: Company Overview
Table 6.7 BioPharma Solutions: Overview of Service Portfolio
Table 6.8 BioPharma Solutions: Sterile Manufacturing Facilities
Table 6.9 BioPharma Solutions: Recent Developments and Future Outlook
Table 6.10 BioReliance: Company Overview
Table 6.11 BioReliance: Overview of Service Portfolio
Table 6.12 BioReliance: Sterile Manufacturing Facilities
Table 6.13 BioReliance: Recent Developments and Future Outlook
Table 6.14 Catalent Biologics: Company Overview
Table 6.15 Catalent Biologics: Overview of Service Portfolio
Table 6.16 Catalent Biologics: Sterile Manufacturing Facilities
Table 6.17 Catalent Biologics: Recent Developments and Future Outlook
Table 6.18 Patheon: Company Overview
Table 6.19 Patheon: Overview of Service Portfolio
Table 6.20 Patheon: Sterile Manufacturing Facilities
Table 6.21 Patheon: Recent Developments and Future Outlook
Table 7.1 Biologics Fill / Finish Service Providers in Europe: List of Profiled Companies
Table 7.2 Boehringer Ingelheim BioXcellence: Company Overview
Table 7.3 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Table 7.4 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 7.5 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 7.6 Lonza: Company Overview
Table 7.7 Lonza: Overview of Service Portfolio
Table 7.8 Lonza: Sterile Manufacturing Facilities
Table 7.9 Lonza: Recent Developments and Future Outlook
Table 7.10 Pierre Fabre: Company Overview
Table 7.11 Pierre Fabre: Overview of Service Portfolio
Table 7.12 Pierre Fabre: Sterile Manufacturing Facilities
Table 7.13 Pierre Fabre: Recent Developments and Future Outlook
Table 7.14 Recipharm: Company Overview
Table 7.15 Recipharm: Overview of Service Portfolio
Table 7.16 Recipharm: Sterile Manufacturing Facilities
Table 7.17 Recipharm: Recent Developments and Future Outlook
Table 7.18 Wacker Biotech: Company Overview
Table 7.19 Wacker Biotech: Overview of Service Portfolio
Table 7.20 Wacker Biotech: Sterile Manufacturing Facilities
Table 7.21 Wacker Biotech: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Asia-Pacific: List of Profiled Companies
Table 8.2 Asymchem: Company Overview
Table 8.3 Asymchem: Overview of Service Portfolio
Table 8.4 Asymchem: Sterile Manufacturing Facilities
Table 8.5 Asymchem: Recent Developments and Future Outlook
Table 8.6 Syngene: Company Overview
Table 8.7 Syngene: Overview of Service Portfolio
Table 8.8 Syngene: Recent Developments and Future Outlook
Table 8.9 Takara Bio: Company Overview
Table 8.10 Takara Bio: Overview of Service Portfolio
Table 8.11 Takara Bio: Recent Developments and Future Outlook
Table 8.12 WuXi Biologics: Company Overview
Table 8.13 WuXi Biologics: Overview of Drug Product Services
Table 8.14 WuXi Biologics: Sterile Manufacturing Facilities
Table 8.15 WuXi Biologics: Recent Developments and Future Outlook
Table 9.1 Biologics Fill / Finish Service Providers: Partnerships and Collaborations, 2013-2020
Table 9.2 Partnerships and Collaborations: Information on Types of Services Offered, 2013-2020
Table 9.3 Partnerships and Collaborations: Information on Types of Biologics Involved, 2013-2020
Table 10.1 Biologics Fill / Finish Service Providers: Recent Expansions, 2013-2021 (till January)
Table 10.2 Recent Expansions, 2013-2021 (till January): Information on Type of Packaging
Table 10.3 Recent Expansions, 2013-2021 (till January): Information on Types of Services
Table 10.4 Recent Expansions, 2013-2021 (till January): Information on Types of Biologics
Table 11.1 Average Fill / Finish Capacity for Ampoules (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.2 Average Fill / Finish Capacity for Cartridges (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.3 Average Fill / Finish Capacity for Syringes (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.4 Average Fill / Finish Capacity for Vials (Number of Units Filled) by Company Size (Sample Data Set)
Table 11.5 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size
Table 11.6 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size
Table 11.7 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size
Table 11.8 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size
Table 11.9 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
Table 11.10 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size
Table 11.11 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size
Table 11.12 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size
Table 12.1 Global Biologics Fill / Finish Services: Annual Supply for Outsourcing, 2021-2030 (Million Liters)
Table 16.1 Patent Expiry of Biologics, 2021-2023
Table 17.1 Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
Table 17.2 List of Pharmaceutical Robotics Manufacturers
Table 17.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 18.1 List of Companies Supplying Ready-to-Use Packaging Components
Table 19.1 Biologics Fill / Finish Service Providers: Summary of the Report
Table 21.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 21.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 21.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 21.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 21.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging
Table 21.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Involved and Type of Packaging Form
Table 21.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 21.8 Biologics Fill / Finish Service Providers: Distribution by Type of Additional Services Offered
Table 21.9 AbbVie: Annual Revenues, 2015 - 2020 (USD Billion)
Table 21.10 Merck KGaA: Annual Revenues, 2014 - 9M 2020 (EUR Billion)
Table 21.11 Merck KGaA: Annual Revenues by Business Segment, 9M 2020 (EUR Billion)
Table 21.12 Catalent Biologics: Annual Revenues, 2015 - 2020 (USD Billion)
Table 21.13 Thermo Fisher Scientific: Annual Revenues, 2014 - 9M 2020 (USD Billion)
Table 21.14 Patheon: Annual Revenues, 2012 - H1 2017 (USD Million)
Table 21.15 Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Table 21.16 Boehringer Ingelheim BioXcellence: Annual Revenues, 2014 - H1 2020 (EUR Billion)
Table 21.17 Lonza: Annual Revenues, 2014 - H1 2020 (CHF Million)
Table 21.18 Pierre Fabre: Annual Revenues, 2015 - 2018 (EUR Billion)
Table 21.19 Recipharm: Annual Revenues, 2012 - 9M 2020 (SEK Billion)
Table 21.20 Recipharm: Revenues by Business Divisions, 9M 2020 (SEK Billion)
Table 21.21 Wacker Chemie: Annual Revenues, 2015 - 2020 (EUR Billion)
Table 21.22 Asymchem: Annual Revenues, 2015 - 2019 (USD Million)
Table 21.23 Samsung Biologics: Annual Revenues, FY 2016 - FY 2020 (KRW Billion)
Table 21.24 Syngene: Annual Revenues, FY 2016 - 9M FY 2021 (INR Million)
Table 21.25 Takara Bio: Annual Revenues, FY 2016 - H1 FY 2021 (JPY Billion)
Table 21.26 WuXi Biologics: Annual Revenues, 2014 - H1 2020 (RMB Million)
Table 21.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2020
Table 21.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 21.29 Partnerships and Collaborations: Distribution by Scale of Operation
Table 21.30 Partnerships and Collaborations: Distribution by Types of Services Offered
Table 21.31 Partnerships and Collaborations: Distribution by Types of Processes
Table 21.32 Partnerships and Collaborations: Distribution by Types of Biologics Involved and Type of Services Offered
Table 21.33 Partnerships and Collaborations: Most Active Players
Table 21.34 Partnerships and Collaborations: Geographical Analysis
Table 21.35 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 21.36 Partnerships and Collaborations: Distribution by Geographical Location of Facilities
Table 21.37 Recent Expansions: Distribution by Year of Expansion, 2013-2021 (till January)
Table 21.38 Recent Expansions: Distribution by Type of Expansion
Table 21.39 Recent Expansions: Distribution by Type of Packaging
Table 21.40 Recent Expansions: Distribution by Type of Expansion and Type of Service
Table 21.41 Recent Expansions: Distribution by Type of Biologic Involved
Table 21.42 Recent Expansions: Distribution by Type of Biologic and Scale of Operation
Table 21.43 Recent Expansions: Distribution by Geographical Location
Table 21.44 Recent Expansions: Distribution by Most Active Players
Table 21.45 Recent Expansions: Distribution by Location of Expansion Project
Table 21.46 Recent Expansions in North America: Distribution by Type of Service Offered and Type of Biologic Involved
Table 21.47 Recent Expansions in Europe: Distribution by Type of Service and Type of Biologic
Table 21.48 Recent Expansions in Asia-Pacific: Distribution by Type of Service and Type of Biologic
Table 21.49 Capacity for Filling Ampoules: Distribution by Company Size (Sample Data Set)
Table 21.50 Capacity for Filling Cartridges: Distribution by Company Size (Sample Data Set)
Table 21.51 Capacity for Filling Syringes: Distribution by Company Size (Sample Data Set)
Table 21.52 Capacity for Filling Vials: Distribution by Company Size (Sample Data Set)
Table 21.53 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Type of Packaging (Million Units)
Table 21.54 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Company Size (Million Units)
Table 21.55 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Scale of Operation (Million Units)
Table 21.56 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Headquarters (Million Units)
Table 21.57 Global Fill / Finish Capacity (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.58 Global Fill / Finish Capacity (by Fill Volume): Distribution by Type of Packaging (Kilo Liters)
Table 21.59 Global Fill / Finish Capacity (by Fill Volume): Distribution by Company Size (Kilo Liters)
Table 21.60 Global Fill / Finish Capacity (by Fill Volume): Distribution by Scale of Operation (Kilo Liters)
Table 21.61 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Headquarters (Kilo Liters)
Table 21.62 Global Fill / Finish Capacity (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Kilo Liters)
Table 21.63 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.64 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.65 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.66 Global Fill / Finish Capacity for Ampoules (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.67 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Company Size (Liters)
Table 21.68 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.69 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.70 Global Fill / Finish Capacity for Ampoules (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.71 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.72 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.73 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.74 Global Fill / Finish Capacity for Cartridges (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.75 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Company Size (Liters)
Table 21.76 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.77 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.78 Global Fill / Finish Capacity for Cartridges (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.79 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Company Size
Table 21.80 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.81 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.82 Global Fill / Finish Capacity for Syringes (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.83 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Company Size (Liters)
Table 21.84 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.85 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.86 Global Fill / Finish Capacity for Syringes (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.87 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Company Size (Thousand Units)
Table 21.88 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Scale of Operation (Thousand Units)
Table 21.89 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Headquarters (Thousand Units)
Table 21.90 Global Fill / Finish Capacity for Vials (by Number of Units Filled): Distribution by Location of Fill / Finish Facilities (Thousand Units)
Table 21.91 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Company Size (Liters)
Table 21.92 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Scale of Operation (Liters)
Table 21.93 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Headquarters (Liters)
Table 21.94 Global Fill / Finish Capacity for Vials (by Fill Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 21.95 Global Demand for Biologics Fill / Finish Services (Million Liters)
Table 21.96 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging (Kilo Liters)
Table 21.97 Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic (Kilo Liters)
Table 21.98 Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area (Kilo Liters)
Table 21.99 Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location (Kilo Liters)
Table 21.100 Global Biologics Fill / Finish Services: Demand and Supply, 2021-2030
Table 21.101 Overall Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 21.102 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.103 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.104 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.105 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.106 Biologics Fill / Finish Services Market, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.107 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.108 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.109 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.110 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.111 Biologics Fill / Finish Services Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.112 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.113 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.114 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.115 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.116 Biologics Fill / Finish Services Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.117 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Countries (USD Million)
Table 21.118 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Packaging (USD Million)
Table 21.119 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.120 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.121 Biologics Fill / Finish Services Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.122 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.123 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.124 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.125 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.126 Biologics Fill / Finish Services Market for Ampoules, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.127 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.128 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.129 Biologics Fill / Finish Services Market for Ampoules in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.130 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.131 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.132 Biologics Fill / Finish Services Market for Ampoules in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.133 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.134 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.135 Biologics Fill / Finish Services Market for Ampoules in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.136 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.137 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.138 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.139 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.140 Biologics Fill / Finish Services Market for Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.141 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.142 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.143 Biologics Fill / Finish Services Market for Cartridges in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.144 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.145 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.146 Biologics Fill / Finish Services Market for Cartridges in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.147 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.148 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.149 Biologics Fill / Finish Services Market for Cartridges in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.150 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.151 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.152 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.153 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.154 Biologics Fill / Finish Services Market for Syringes, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.155 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.156 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.157 Biologics Fill / Finish Services Market for Syringes in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.158 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.159 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.160 Biologics Fill / Finish Services Market for Syringes in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.161 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.162 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.163 Biologics Fill / Finish Services Market for Syringes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.164 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Million)
Table 21.165 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.166 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.167 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.168 Biologics Fill / Finish Services Market for Vials, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Geographical Region (USD Million)
Table 21.169 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.170 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.171 Biologics Fill / Finish Services Market for Vials in North America, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.172 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.173 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.174 Biologics Fill / Finish Services Market for Vials in Europe, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.175 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 21.176 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Type of Biologic (USD Million)
Table 21.177 Biologics Fill / Finish Services Market for Vials in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 21.178 New Molecular Entities Approved by the FDA, 2011-2020

List Of Companies

  1. 3P Biopharmaceuticals
  2. Aalto Scientific
  3. ABB
  4. AbbVie
  5. AbbVie Contract Manufacturing
  6. Abzena
  7. ACG
  8. ACIC Pharmaceutical Machinery
  9. AdaptVac
  10. ADC Biotechnology
  11. Adimmune 
  12. Advanced BioScience Laboratories
  13. Affinity Life Sciences
  14. Afton Scientific
  15. Agilis Biotherapeutics
  16. AJ Biologics
  17. Ajinomoto Bio-Pharma Services
  18. Akron Biotech
  19. AKSO
  20. Akums Drugs and Pharmaceuticals
  21. Alanza
  22. Alcami
  23. Alcon
  24. Aldevron
  25. Alkermes
  26. Althea
  27. Althea Technologies
  28. Amatsigroup
  29. Ambica Pharma Machines
  30. Amgen
  31. Amicus Therapeutics 
  32. AMRI
  33. Anchiano Therapeutics
  34. Anchor Mark
  35. Anthos Therapeutics
  36. apceth Biopharma
  37. APG Europe
  38. Aptar Pharma
  39. Aptuit
  40. Arabio
  41. ARaymond Life
  42. Arch Biopartners
  43. ARISTO
  44. Aseptic Technologies
  45. Asklepios BioPharmaceutical
  46. AST
  47. AstraZeneca
  48. Asymchem
  49. Ausia BioTech
  50. Austrianova
  51. Automated Systems of Tacoma
  52. Avrio Biopharmaceuticals
  53. AWS Bio-Pharma Technologies
  54. Axcellerate Pharma
  55. Baccinex
  56. Bausch & Ströbel
  57. BAUSCH Advanced Technology Group (BATG)
  58. Bayer
  59. Berkshire Sterile Manufacturing
  60. Binex
  61. Bio Elpida
  62. Bio-Concept Laboratories
  63. BioConnection
  64. Biofabri 
  65. Biogen
  66. BioMARC
  67. Biomay
  68. Biomedical Advanced Research and Development Authority (BARDA)
  69. BioNTech IMFS
  70. BioPharma Solutions
  71. BioReliance
  72. BioTechLogic
  73. BioTechnique
  74. BioTechniques
  75. Biovian
  76. BirgiMefar
  77. Boehringer Ingelheim BioXcellence
  78. Bolt Biotherapeutics
  79. Boston Children’s Hospital
  80. Bristol-Myers Squibb
  81. Bryllan
  82. BSP Pharmaceuticals
  83. Burrard Pharmaceuticals
  84. Cangene Corporation
  85. Canton Biologics
  86. CARBOGEN AMCIS
  87. Catalent Biologics
  88. Celgene
  89. Cell Culture Company 
  90. Cellin Technologies
  91. Celonic
  92. Cenexi
  93. Cerbios-Pharma
  94. Cerium Pharmaceuticals
  95. ChemPartner
  96. Chime Biologics
  97. China Gateway Biologics
  98. CinnaGen
  99. Citryll
  100. CMAB Biopharma
  101. CMC Biologics
  102. Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
  103. Cobra Biologics
  104. Cognate BioServices
  105. Coldstream Laboratories
  106. Colorado State University
  107. Columbus Venture Partners
  108. Comecer
  109. Cook Pharmica
  110. CordenPharma
  111. Creative Biolabs
  112. Crystal Pharma
  113. CureVac
  114. CytoDyn
  115. Cytovance Biologics
  116. Daikyo Seiko
  117. Dalton Pharma Services
  118. Dara Pharma
  119. Datwyler Sealing Solutions
  120. DENSO 
  121. Dhruv Life Sciences
  122. Disposable Lab
  123. DM Bio
  124. DSM Pharmaceutical Products
  125. DWK Life Sciences
  126. EirGen Pharma
  127. EirGenix
  128. Eli Lilly
  129. EMA Pharmaceuticals
  130. Emcure Pharmaceuticals
  131. Emergent BioSolutions
  132. Esco Aster
  133. Etinpro
  134. EuBiologics
  135. EUCODIS Bioscience
  136. Eurofins BioPharma Product Testing Netherlands
  137. Eurofins Scientific
  138. EVER Pharma
  139. Exelead
  140. Experic
  141. Extract Technology
  142. FANUC America
  143. Fareva
  144. FinVector 
  145. Formosa Laboratories
  146. Fresenius Kabi Contract Manufacturing
  147. FUJIFILM Diosynth Biotechnologies
  148. GC Pharma
  149. GEA
  150. Genentech
  151. GeneQuantum Healthcare
  152. Generic Specialities
  153. GenIbet Biopharmaceuticals
  154. Genovior Biotech 
  155. Genprex
  156. Gerresheimer
  157. Getinge
  158. GigaGen
  159. Gilead
  160. GlaxoSmithKline 
  161. GLyPharma 
  162. Goodwin Biotechnology
  163. GP Pharm
  164. Grand River Aseptic Manufacturing
  165. Groninger
  166. GTCR
  167. Gulf Biotech
  168. HALIX
  169. Hameln Pharma
  170. Handl Therapeutics
  171. Hansa Biopharma
  172. Hapten Sciences
  173. Health Biotech
  174. Healthcare Pharmaceuticals
  175. Hepalink
  176. Hetero Drugs
  177. Hisun Pharmaceuticals USA
  178. Hookipa Pharma
  179. Hospira One 2 One
  180. Humanigen
  181. Hybio Pharmaceutical
  182. Hycult Biotech
  183. IDT Biologika
  184. IMA Group
  185. Immune Pharmaceuticals
  186. Immunex
  187. Infectious Disease Research Institute
  188. Injectalia
  189. Intas Pharmaceuticals
  190. Integrity Bio
  191. Irvine Pharmaceutical Services
  192. Istituto Biochimico Italiano Giovanni Lorenzini 
  193. Janssen Pharmaceuticals
  194. JHL Biotech
  195. Johnson & Johnson
  196. JOINN Biologics
  197. Jubilant HollisterStier
  198. Kanda BioTech
  199. Kaneka Eurogentec
  200. Kawasaki Heavy Industries
  201. Kaysersberg Pharmaceuticals
  202. Kemwell Biopharma
  203. Klenzaids
  204. Kohlberg and Mubadala
  205. KUKA
  206. Laboratorios Farmaceuticos ROVI
  207. Laekna Therapeutics
  208. LamKap Bio
  209. Lava Therapeutics
  210. Liof Pharma
  211. Lonza
  212. LSNE Contract Manufacturing
  213. Lubrizol
  214. LuinaBio
  215. Lyophilization Technology
  216. M&O Perry Industries
  217. MabPlex
  218. Madison Dearborn Partners
  219. Marchesini Group
  220. MassBiologics
  221. Massman Automation Designs
  222. MaSTherCell
  223. MEDInstill
  224. Merck
  225. Microdermics 
  226. Millmount Healthcare (acquired by PCI Pharma Services)
  227. Miltenyi Biotec
  228. Minaris Regenerative Medicine
  229. Mitsubishi Electric
  230. Moderna
  231. Mycenax Biotech
  232. Najít Technologies
  233. National Institutes of Health
  234. NBE-Therapeutics
  235. Nikon CeLL innovation
  236. Ningbo Zhengli Pharmaceutical Packing
  237. Nipro PharmaPackaging
  238. Nitto Avecia Pharma Services
  239. Nitto Denko Avecia
  240. Northway Biotechpharma
  241. Nova Laboratories
  242. Novartis
  243. Novasep
  244. Noveome Biotherapeutics
  245. Novex Innovations
  246. Novo Nordisk
  247. Ology Bioservices
  248. OmniChem
  249. Ompi
  250. OMRON Industrial Automation
  251. oncomed manufacturing
  252. Oncotec Pharma Produktion
  253. OPKO Health
  254. OPTIMA
  255. Oryn Therapeutics
  256. OSO Biopharmaceuticals Manufacturing (acquired by AMRI)
  257. Ottawa Hospital Research Institute
  258. Oxford BioMedica
  259. Pace Analytical
  260. PaizaBio
  261. Pall Life Sciences
  262. Panacea Pharmaceuticals
  263. Paragon Bioservices
  264. Particle Measuring Systems
  265. Partners Group
  266. Patheon
  267. PCI Pharma Services
  268. Penn Pharmaceutical Services
  269. Permira
  270. Pfizer
  271. Pfizer CentreOne
  272. Pharmaceutical Packaging Professionals
  273. Pierre Fabre
  274. Piramal Pharma Solutions
  275. Polpharma Biologics
  276. Polymun Scientific
  277. Praxis Pharmaceutical
  278. PrimaPharma
  279. Prince Sterilization Services
  280. PSC Biotech
  281. PYRAMID Laboratories
  282. Quality BioResources
  283. QureBio
  284. Recipharm
  285. Regeneron Pharmaceuticals
  286. Reliance Life Sciences
  287. Rentschler Biopharma
  288. Rentschler Fill Solutions
  289. Revance Therapeutics
  290. Roche
  291. Romaco
  292. Rommelag CMO
  293. RoslinCT
  294. ROTA
  295. Ruibo Bio-Technology
  296. Russian Direct Investment Fund (RDIF)
  297. Samsung Bioepis
  298. Samsung Biologics
  299. Sandoz
  300. Sanofi
  301. Saudi Biotechnology Manufacturing
  302. Schematic Engineering Industries
  303. SCHOTT 
  304. ScinoPharm
  305. Seiko Epson
  306. Selecta Biosciences
  307. Sensorion
  308. Shengnuo Peptide
  309. Sherpa Clinical Packaging Packaging (acquired by PCI Pharma Services)
  310. Shibuya
  311. Shree Bhagwati Machtech (India)
  312. SialoCarb
  313. Siam Bioscience
  314. Siegfried Holding
  315. Singota Solutions
  316. Sio Gene Therapies
  317. SiO2 Medical Products
  318. SIRION Biotech 
  319. Sirton Pharmaceuticals
  320. SKAN
  321. Snowbell Machines
  322. SP
  323. Square Pharmaceuticals
  324. Staubli
  325. Steriline
  326. Surrozen
  327. Swissfillon
  328. Symbiosis Pharmaceutical
  329. Symphogen
  330. SynCo Bio Partners
  331. Syngene
  332. Synklino
  333. Syntegon
  334. Sypharma
  335. National Health Research Institutes (NHRI)
  336. Takara Bio
  337. Tanvex BioPharma
  338. Taysha Gene Therapies
  339. Tekpak
  340. The Carlyle Group
  341. Therapure Biomanufacturing
  342. Thermo Fisher Scientific
  343. Tofflon
  344. Transcoject
  345. TriPharm Services (acquired by Alcami)
  346. TRUKING
  347. Tubulis
  348. U.S. Army Contracting Command
  349. UCB
  350. Ultragenyx Pharmaceutical
  351. Universal Robots
  352. University of Queensland
  353. USV
  354. Vanrx
  355. Vaxine
  356. VBI Vaccines
  357. Vetter Pharma
  358. VGXI
  359. Vibalogics
  360. Vaccine and Infectious Disease Organization (VIDO)
  361. Vigene Biosciences
  362. Viralgen
  363. VxP Biologics
  364. WACKER Biotech
  365. Waisman Biomanufacturing
  366. Watson-Marlow Fund
  367. West Pharmaceutical Services
  368. WuXi Biologics
  369. Wuxi Fortune Pharmaceutical
  370. Wuxi Griffin
  371. Yaskawa Electric
  372. Yposkesi

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com